Add BrightSurf on Google Email

Alzheimer’s drug development pipeline: promising therapies, pharma investment drive momentum in clinical trials

The Alzheimer's disease development pipeline has seen an increase in promising therapies and pharma investment, driving momentum in clinical trials. The pipeline currently has 187 clinical trials, with recent FDA approvals for two disease-modifying therapies, and more on the way.

SourceUniversity of Nevada, Las Vegas·JournalAlzheimer s & Dementia Translational Research & Clinical Interventions·TypeSystematic review·DateMay 25, 2023

Researchers identify strong T-cell response in first-in-human nanoparticle HIV vaccine

The study, published in Science Translational Medicine, shows robust T-cell responses in volunteers participating in a phase 1 clinical trial of a self-assembling nanoparticle HIV vaccine. The antigen used stimulates VRC01-class B cells, an immune response considered promising for boosting in further studies.

SourceFred Hutchinson Cancer Center·JournalScience Translational Medicine·TypeRandomized controlled/clinical trial·DateMay 24, 2023

Mays Cancer Center conducts only clinical trial in America of a specific drug combination for lethal brain cancer glioblastoma

A clinical trial combining TVB-2640 and bevacizumab showed a six-month progression-free survival improvement in patients with recurrent high-grade glioblastoma, warranting further study. The treatment's side effects were mild, but the overall survival of participants was not statistically significant compared to historic controls.

SourceUniversity of Texas Health Science Center at San Antonio·JournalClinical Cancer Research·TypeExperimental study·DateMay 23, 2023

ASCO: Targeted therapy for early breast cancer, progress treating recurrent glioma, PSMA PET scan advances and more

Researchers from the UCLA Jonsson Comprehensive Cancer Center are presenting findings on combination therapies for breast cancer and a potential new treatment for patients with recurrent glioma. A phase 3 study evaluating vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation is also be...

Leadless pacemakers soon available for all patients

An international consortium led by Amsterdam UMC has developed an improved version of the wireless pacemaker, enabling placement in both the atrium and ventricle of the heart. This innovation expands treatment options for patients with slow heart rhythms, improving contraction and reducing the need for multiple mini pacemakers.

SourceAmsterdam University Medical Center·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateMay 22, 2023

A Spanish team presents the first pharmacological treatment able to improve cardiac function in stiff-heart syndrome

Researchers have developed a pharmacological treatment that improves cardiac function in patients with stiff-heart syndrome, a condition caused by amyloid protein deposition. The new drug reduces amyloid protein deposits and shows promise in reversing established disease symptoms.

SourceCentro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.)·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateMay 20, 2023

Novel percutaneous ventricular assist device feasibile in patients undergoing high-risk percutaneous coronary interventions (HRPCI)

A novel low-profile pVAD system demonstrated 100% procedural success and no device-related adverse events in a first-in-human trial. The device supports cardiovascular hemodynamics with minimal hemolysis and low risk of vascular complications, aiming to minimize morbidity and improve patient outcomes

Coronary bioresorbable scaffolds nearly as safe and effective as conventional metal stents for heart disease patients

A global clinical trial found that bioresorbable vascular scaffolds (BVS) are nearly as safe and effective as conventional metal stents in treating coronary artery disease. The study, led by a researcher from the Mount Sinai Hospital, showed improved outcomes for patients when properly implanted.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalJournal of the American College of Cardiology·TypeRandomized controlled/clinical trial·DateMay 17, 2023

Chinese Medical Journal article explores how bispecific antibodies could bring new hope to patients with lung cancer

Researchers from China explore the mechanisms of action and clinical data of bispecific antibodies, which have shown promise in increasing cytotoxicity against cancerous cells and enhancing immune response towards tumor clearance. Several bsAbs are being evaluated in phase I-III clinical trials for lung cancer treatment.

SourceCactus Communications·JournalChinese Medical Journal·DateMay 16, 2023

Alternating estrogen and anti-estrogen therapies is effective in treating metastatic breast cancer

Researchers at Dartmouth Cancer Center found that alternating estrogen stimulation and anti-estrogen therapy is an effective treatment for patients with metastatic or advanced ER+ breast cancer. The POLLY trial showed that 42% of patients experienced tumor stabilization, while no patients discontinued treatment due to side effects.

SourceDartmouth Health·JournalClinical Cancer Research·TypeRandomized controlled/clinical trial·DateMay 15, 2023

‘A smarter kinder approach to treatment’ for anal cancer

A recent clinical trial, PLATO, demonstrated that lowering the dose and duration of radiotherapy treatments for anal cancer reduces side effects without compromising cancer cure rates. The treatment involves intensity modulated radiotherapy (IMRT), which allows for personalized doses to be applied to visible tumors.

SourceUniversity of Leeds·TypeRandomized controlled/clinical trial·DateMay 15, 2023

Combined delivery of engineered virus with immunotherapy is safe and improves outcomes in subset of patients with glioblastoma

A Phase I/II clinical trial combining intratumoral delivery of an engineered oncolytic virus with subsequent immunotherapy improved survival outcomes in a subset of patients with recurrent glioblastoma. The study demonstrated the combination was well-tolerated, with no dose-limiting toxicities.

Cervical cancer screening doubles when under-screened women are mailed testing kits

Researchers found mailing HPV self-collection tests and offering assistance improved cervical cancer screening nearly two-fold among low-income women. Screening uptake increased to 72% among women who received mailed HPV kits, compared to 37% for those with scheduling assistance alone.

SourceUNC Lineberger Comprehensive Cancer Center·JournalThe Lancet Public Health·TypeRandomized controlled/clinical trial·DateMay 11, 2023

Home measurement of blood oxygen levels by corona patients themselves easily applicable

A study by UMC Utrecht shows that corona patients can measure their blood oxygen levels at home using a pulse oximeter, feeling safe and experiencing more control. This method does not increase GP visits or hospitalization but contributes to relieving caregivers and keeping healthcare affordable.

SourceUniversity Medical Center Utrecht·JournalBritish Journal of General Practice·TypeRandomized controlled/clinical trial·DateMay 10, 2023

Deaf-to-deaf weight loss program helps participants drop pounds

A specialized weight loss program for Deaf people, designed and led by Deaf individuals, resulted in significant weight loss among participants. The Deaf Weight Wise program focused on lifestyle changes, social support, and cultural relevance, leading to a higher retention rate and better outcomes compared to mainstream programs.

SourceUniversity of Rochester Medical Center·JournalObesity·TypeRandomized controlled/clinical trial·DateMay 8, 2023

Study: ChemoID platform-predicted treatments lead to longer survival for glioblastoma patients

A multi-institutional phase 3 clinical trial found that a cancer stem cell test can accurately decide more effective treatments and lead to increased survival for patients with recurrent glioblastoma. ChemoID, a CLIA-accredited diagnostic test, was used to select chemotherapy treatments, resulting in significantly lower risk of death a...

SourceUniversity of Cincinnati·JournalCell Reports Medicine·TypeRandomized controlled/clinical trial·DateMay 5, 2023

Systemic AL amyloidosis: Current approach and future direction

Researchers review current treatment updates for systemic light chain (AL) amyloidosis, highlighting the need for early diagnosis and effective maintenance therapy. The article discusses the relationship between AL amyloidosis and monoclonal gammopathy of undetermined significance (MGUS), emphasizing the importance of regular monitoring.

SourceImpact Journals LLC·JournalOncotarget·TypeCommentary/editorial·DateMay 5, 2023

Criteria for selecting who can enroll in multiple myeloma clinical trials may exclude patients from racial and ethnic minorities

A study found that clinical trial eligibility criteria may be a barrier to enrollment of patients from underrepresented racial and ethnic groups. Black patients were most likely to be deemed ineligible due to blood cell counts or lack of prior treatments, while Asian patients had the lowest rate of ineligibility.

Study finds fluorescent guide can help detect tumor left behind after breast cancer surgery

A clinical trial of 406 patients found that a fluorescent agent allowed surgeons to identify and remove residual tumor tissue with favorable results. The technique showed promising results in detecting tumor tissue missed by standard lumpectomy procedures, potentially avoiding second surgeries for positive margins.

SourceMass General Brigham·JournalNEJM Evidence·TypeRandomized controlled/clinical trial·DateMay 3, 2023

Boxing can take the fight to Parkinson’s Disease

A new study published by Edith Cowan University found that boxing programs can improve symptoms of Parkinson's Disease, including fatigue and sleep, in early-stage patients. The program combined elements of exercise, computerized cognitive training, and socialization into a single activity.

SourceEdith Cowan University·JournalPhysical Medicine and Rehabilitation·TypeObservational study·DateMay 2, 2023

Endovascular treatment more likely to avoid amputation or death for limb-threatening artery disease

A randomized controlled trial shows that a best endovascular treatment first revascularisation strategy is more effective in preventing major amputation and death than a vein bypass first strategy for patients with chronic limb-threatening ischaemia. The study, BASIL-2, recruited 345 patients from the UK, Sweden, and Denmark and found ...

SourceUniversity of Birmingham·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateMay 2, 2023

“Eat, Sleep, Console” reduces hospital stay and need for medication among opioid-exposed infants

Researchers found that the 'Eat, Sleep, Console' (ESC) care approach is more effective than Finnegan Neonatal Abstinence Scoring Tool (FNAST) in assessing and managing opioid-exposed newborns. Newborns cared for with ESC were medically ready for discharge approximately 6.7 days earlier and 63% less likely to receive medication.

SourceNIH/Eunice Kennedy Shriver National Institute of Child Health and Human Development·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateApr 30, 2023

New study looks at role of sleep disruption in dogs with dementia

A new study by North Carolina State University researchers used EEGs on elderly dogs to determine whether brain-wave readings during sleep correlated with signs of cognitive decline. The study found that dogs with more advanced dementia suffered from more sleep disruptions and slept less overall than dogs with normal cognitive function.

SourceNorth Carolina State University·JournalFrontiers in Veterinary Science·DateApr 28, 2023

NRG Oncology study results confirm conventional external beam radiotherapy should remain standard of care in treating localized vertebral metastases of the spine

The NRG Oncology study found that stereotactic radiosurgery was not superior to conventional external beam radiotherapy in terms of pain response, and even showed worse pain response at 3 months. Conventional radiotherapy remained effective with a 50-60% pain relief rate, but only lasting four months.

SourceNRG Oncology·JournalJAMA Oncology·DateApr 27, 2023

Patient-reported outcomes from an NRG Oncology study of androgen deprivation therapy with dose-escalated radiotherapy for intermediate-risk prostate cancer show no clinically meaningful differences in scores at one year post-treatment

A recent study published in Journal of Clinical Oncology found that dose-escalated radiotherapy with short-term androgen deprivation therapy showed no significant impact on urinary or bowel quality of life for men with intermediate-risk prostate cancer. However, the treatment did significantly decrease hormone and sexual quality of lif...

SourceNRG Oncology·JournalJournal of Clinical Oncology·DateApr 27, 2023

NRG Oncology trial does not improve overall survival, but shows improvements in several clinical outcomes for men with intermediate-risk prostate cancer

The study found that dose-escalated radiotherapy with short-term androgen deprivation therapy improved rates of biochemical failure, distant metastases, and prostate cancer-specific mortality. However, the trial did not meet its primary endpoint of improving overall survival for men with intermediate-risk prostate cancer.

SourceNRG Oncology·JournalJournal of Clinical Oncology·DateApr 27, 2023